Medical University of Innsbruck, Department of Paediatrics II, Division of Neonatology, Austria.
Medical University of Innsbruck, Department of Paediatrics III, Division of Cardiology, Pulmonology, Allergology and Cystic Fibrosis, Austria.
Pediatr Neonatol. 2020 Feb;61(1):84-91. doi: 10.1016/j.pedneo.2019.06.011. Epub 2019 Jul 3.
To determine the rate of patent ductus arteriosus after prophylactic low-dose paracetamol administration, the impact on outcome parameters, possible treatment side-effects and the influence on pain perception.
We report retrospective single-centre outcome data of premature infants ≤ 32 weeks of gestation (n = 476). The intervention group received intravenous paracetamol, the control group obtained no preventive therapy. Ductal closure rate and outcome parameters were compared between the two groups. Adverse effects were determined by laboratory parameters. For the assessment of pain the Bernese Pain Scale for Neonates was used.
The rate of patent ductus arteriosus was significantly lower in the paracetamol-treated group compared to the control group (13.6% vs. 38.2%, p < 0.001). With regard to secondary outcome parameters, severe and moderate bronchopulmonary dysplasia (2.7% vs. 7.4%, p = 0.023), severe retinopathy of prematurity (0% vs. 4.4%, p = 0.002) and late onset sepsis (2.7% vs. 8.3%, p = 0.009) were significantly less frequent in the paracetamol group. Except for a 1.5-fold increased risk for hyperbilirubinemia (86.0% vs. 77.6%, p = 0.035) in the paracetamol group following treatment, no significant differences in laboratory parameters were found. Relating to pain, the administration of Glucose 33% was significantly more often necessary in the control group compared to the paracetamol-treated group (mean 13.48 vs. 8.71, p < 0.001), just as the need for additional treatment with systemic analgesics, which was more frequent in the control group (mean 0.72 vs. 0.57, p = 0.361).
In our study we were able to show a significantly lower rate of patent ductus arteriosus after prophylactic paracetamol administration without serious adverse effect, but a beneficial influence of this regime on the patient's pain perception.
为了确定预防性低剂量扑热息痛给药后动脉导管未闭的发生率,以及其对结局参数的影响、可能的治疗副作用和对疼痛感知的影响。
我们报告了一项回顾性单中心研究的结果,研究对象为≤32 周龄的早产儿(n=476)。干预组接受静脉注射扑热息痛,对照组未接受预防性治疗。比较两组之间的动脉导管未闭关闭率和结局参数。通过实验室参数确定不良反应。使用伯尔尼新生儿疼痛量表评估疼痛。
与对照组相比,扑热息痛治疗组的动脉导管未闭发生率显著降低(13.6%比 38.2%,p<0.001)。在次要结局参数方面,严重和中度支气管肺发育不良(2.7%比 7.4%,p=0.023)、严重早产儿视网膜病变(0%比 4.4%,p=0.002)和晚发性败血症(2.7%比 8.3%,p=0.009)的发生率在扑热息痛组显著降低。除治疗后扑热息痛组胆红素升高的风险增加 1.5 倍(86.0%比 77.6%,p=0.035)外,两组之间的实验室参数无显著差异。与疼痛相关,与扑热息痛治疗组相比,对照组中需要更频繁地给予 33%葡萄糖(均值 13.48 比 8.71,p<0.001),以及更频繁地需要给予全身镇痛剂进行额外治疗,对照组中更常见(均值 0.72 比 0.57,p=0.361)。
在我们的研究中,我们能够证明预防性扑热息痛给药后动脉导管未闭的发生率显著降低,且没有严重的不良反应,但这种治疗方案对患者的疼痛感知有有益的影响。